Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John H Rex

Showing results (31-40 of 95) with videos related to

Pageof 10
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 3, 2016
Efficient Delivery of Investigational Antibacterial Agents via Sustainable Clinical Trial NetworksAnthony McDonnell, John H Rex, Herman Goossens, et al.
Antimicrobial Agents and Chemotherapy|February 26, 2004
Combination antifungal therapyMelissa D Johnson, Conan MacDougall, Luis Ostrosky-Zeichner, et al.
Nature Reviews. Drug Discovery|August 21, 2010
An insight into the antifungal pipeline: selected new molecules and beyondLuis Ostrosky-Zeichner, Arturo Casadevall, John N Galgiani, et al.
Nature Communications|August 2, 2019
Designing development programs for non-traditional antibacterial agentsJohn H Rex, Holly Fernandez Lynch, I Glenn Cohen, et al.
The Journal of Antimicrobial Chemotherapy|March 31, 2026
Comment on: Antagonistic in vitro interaction between olorofim and voriconazole against Aspergillus fumigatusCorinne Pinder, Mike Birch, Jason D Oliver, et al.
Nature Reviews. Microbiology|November 21, 2019
Antibiotic development - economic, regulatory and societal challengesChristine Årdal, Manica Balasegaram, Ramanan Laxminarayan, et al.
Health Policy (Amsterdam, Netherlands)|September 11, 2017
Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigationAdrian Towse, Christopher K Hoyle, Jonathan Goodall, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 17, 2004
The design of clinical trials that evaluate antifungal prophylaxis and combination therapy: introduction and overviewJohn H Rex, John R Wingard, Richard Wenzel, et al.
Antimicrobial Agents and Chemotherapy|August 17, 2002
Effect of the echinocandin caspofungin on expression of Candida albicans secretory aspartyl proteinases and phospholipase in vitroJean-Sébastien Ripeau, Francine Aumont, Pierre Belhumeur, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 31, 2020
Antibiotic Development Incentives That Reflect Societal Value of AntibioticsHelen W Boucher, Thomas M File, Vance G Fowler, et al.
Pageof 10

Showing results (31-40 of 95) with videos related to

Sort By:
Pageof 10
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 3, 2016
Efficient Delivery of Investigational Antibacterial Agents via Sustainable Clinical Trial NetworksAnthony McDonnell, John H Rex, Herman Goossens, et al.
Antimicrobial Agents and Chemotherapy|February 26, 2004
Combination antifungal therapyMelissa D Johnson, Conan MacDougall, Luis Ostrosky-Zeichner, et al.
Nature Reviews. Drug Discovery|August 21, 2010
An insight into the antifungal pipeline: selected new molecules and beyondLuis Ostrosky-Zeichner, Arturo Casadevall, John N Galgiani, et al.
Nature Communications|August 2, 2019
Designing development programs for non-traditional antibacterial agentsJohn H Rex, Holly Fernandez Lynch, I Glenn Cohen, et al.
The Journal of Antimicrobial Chemotherapy|March 31, 2026
Comment on: Antagonistic in vitro interaction between olorofim and voriconazole against Aspergillus fumigatusCorinne Pinder, Mike Birch, Jason D Oliver, et al.
Nature Reviews. Microbiology|November 21, 2019
Antibiotic development - economic, regulatory and societal challengesChristine Årdal, Manica Balasegaram, Ramanan Laxminarayan, et al.
Health Policy (Amsterdam, Netherlands)|September 11, 2017
Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigationAdrian Towse, Christopher K Hoyle, Jonathan Goodall, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 17, 2004
The design of clinical trials that evaluate antifungal prophylaxis and combination therapy: introduction and overviewJohn H Rex, John R Wingard, Richard Wenzel, et al.
Antimicrobial Agents and Chemotherapy|August 17, 2002
Effect of the echinocandin caspofungin on expression of Candida albicans secretory aspartyl proteinases and phospholipase in vitroJean-Sébastien Ripeau, Francine Aumont, Pierre Belhumeur, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 31, 2020
Antibiotic Development Incentives That Reflect Societal Value of AntibioticsHelen W Boucher, Thomas M File, Vance G Fowler, et al.
Pageof 10